By proceeding, you agree to our Terms of Use and Privacy Policy.
With TCEs being studied in both hematological and solid tumors (39 and 34 trials respectively), there are now more than one hundred projects in the preclinical stage.
Explore insights on Successful Application in Solid Tumors, Trispecific Antibody Platform for Tumor Specific T-Cell Engagers and T Cell Effector Pathways.
Discover key strategies for the treatment of prostate cancer & ewing sarcoma and selecting the optimal target, design and patient population.
Learn and connect with experts and leaders like Antara Banerjee, Elizabeth Pham, Kate Rochlin, Wanjun Chen, David DiLillo and Jonathan Fisher.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development.
Make faster and better informed drug development decisions In partnership with the world’s leading drug development experts to help you keep up with the pace of preclinical and clinical research developments.
Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). Our platform is commercially validated by well over $1.
Drug discovery remains an expensive and time-consuming process. Promising compounds proceed through clinical trials only to have many fail before FDA approval.
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.